Vasilis Tsimihodimos
Overview
Explore the profile of Vasilis Tsimihodimos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agouridis A, Filippatos T, Kostara C, Tsimihodimos V, Kostapanos M
Turk Kardiyol Dern Ars
. 2025 Mar;
53(2):155-156.
PMID: 40035246
No abstract available.
2.
Doumani G, Theofilis P, Tsimihodimos V, Kalaitzidis R
Life (Basel)
. 2024 Nov;
14(11).
PMID: 39598276
Kidney disease is a public health epidemic affecting 10% of the population worldwide with a constantly rising incidence, and it is an important contributor to morbidity and mortality. Type 2...
3.
Tsimihodimos V, Psoma O
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125686
Over the last few decades, metabolic syndrome coexisting with cardiovascular disease has evolved into a pandemic, making the need for more food-oriented therapeutic approaches and a redefinition of lifestyle imperative,...
4.
Pitsiava S, Dimakopoulos G, Tsimihodimos V, Kotsa K, Koufakis T
Expert Opin Pharmacother
. 2024 Jun;
25(8):1095-1104.
PMID: 38822807
Background: This study aimed to investigate the association between clinical and laboratory parameters and response to therapy with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus...
5.
Agouridis A, Filippatos T, Kostapanos M, Kostara C, Tsimihodimos V
Arch Med Sci Atheroscler Dis
. 2024 Mar;
9:e26-e32.
PMID: 38434941
Introduction: Lipoprotein(a) [Lp(a)] is a strong, genetically determined, pathogenetic factor of atherosclerotic cardiovascular disease (ASCVD). The aim of this post-hoc analysis was to compare the effect of hypolipidemic treatment on...
6.
Koufakis T, Tsimihodimos V, Metallidis S, Kotsa K, Doumas M
Expert Opin Pharmacother
. 2023 Aug;
24(16):1753-1756.
PMID: 37594789
No abstract available.
7.
Kostara C, Bairaktari E, Tsimihodimos V
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768319
The functional status of High-Density Lipoprotein (HDLs) is not dependent on the cholesterol content but is closely related to structural and compositional characteristics. We reported the analysis of HDL lipidome...
8.
Theofilis P, Vordoni A, Tsimihodimos V, Kalaitzidis R
High Blood Press Cardiovasc Prev
. 2023 Jan;
30(1):63-72.
PMID: 36626077
Introduction: Patients with arterial hypertension frequently present with comorbidities that are associated with increased cardiorenal risk, such as metabolic dysfunction-associated fatty liver disease (MAFLD). Aims: Our study aimed to assess...
9.
Psoma O, Makris M, Tselepis A, Tsimihodimos V
J Diabetes Sci Technol
. 2022 Dec;
18(4):956-967.
PMID: 36576014
The introduction of continuous glucose monitoring inaugurated a new era in clinical practice by shifting the characterization of glycemic control from HbA1c to novel metrics. The one that gained widespread...
10.
Papachristoforou E, Liatis S, Psoma O, Kountouri A, Lambadiari V, Tsimihodimos V
J Diabetes Complications
. 2022 Dec;
37(1):108363.
PMID: 36542895
The aim of this study was to assess the effect of the COVID-19 lockdown periods on the metabolic control of patients with type 2 diabetes (T2D) in three academic diabetes...